GlobeNewswire Inc.··NaBlack Diamond Therapeutics Advances Brain Cancer Drug With Promising Phase 2 Data
Black Diamond Therapeutics reports strong Phase 2 data for brain-penetrant cancer drug silevertinib, showing 60% response rate and 86% CNS activity in rare EGFR mutation patients.
BDTXclinical trialoncology